Alcobra Ltd. (ADHD) announced that its investigational New Drug Applications for drug candidate MDX in Attention Deficit Hyperactivity Disorder and Fragile X Syndrome have been put on full clinical hold, following adverse neurological findings in a pre-clinical study.
Alcobra has gapped open dramatically lower Thursday morning and is now down 2.54 at $2.08 on the highest volume of the year. The stock has plunged to a new low for the year.
For comments and feedback contact: editorial@rttnews.com
Business News